First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
暂无分享,去创建一个
W. Mason | D. Melisi | S. Estrem | T. Yap | L. Gandhi | M. Man | A. Cervantes | É. Le Rhun | A. Carpentier | V. Atkinson | S. Kondo | S. Callies | M. Simonelli | S. Ochsenreither | R. Redman | A. van der Westhuizen | Yumin Zhao | Emin Avşar | C. Baldini | M. Löhr | J. Sepúlveda-Sánchez | M. Vieito | R. Cosman | Louise Warren | E. Avşar | Rasha Cosman
[1] A. Varghese,et al. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer , 2021, Journal for ImmunoTherapy of Cancer.
[2] Christopher R. Cabanski,et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. , 2021, The Lancet. Oncology.
[3] D. Capper,et al. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma , 2020, Investigational New Drugs.
[4] G. Giannelli,et al. TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives , 2018, Seminars in Liver Disease.
[5] P. Bose,et al. TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure , 2018, Nature Communications.
[6] J. Tabernero,et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer , 2018, British Journal of Cancer.
[7] Xin-hua Liang,et al. Transforming growth factor-β signaling in head and neck squamous cell carcinoma: Insights into cellular responses. , 2018, Oncology letters.
[8] Camille Stephan-Otto Attolini,et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis , 2018, Nature.
[9] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[10] M. Kalos,et al. Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor , 2017 .
[11] H. Ueno,et al. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer , 2017, Cancer Chemotherapy and Pharmacology.
[12] R. Gibbs,et al. Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.
[13] J. Baselga,et al. First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma , 2014, Clinical Cancer Research.
[14] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[15] A. Hata,et al. Targeting the TGFβ signalling pathway in disease , 2012, Nature Reviews Drug Discovery.
[16] A. Kulkarni,et al. Loss of TGF-β signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation , 2012, Oncogene.
[17] R. Flavell,et al. Autocrine/paracrine TGF-β1 inhibits Langerhans cell migration , 2012, Proceedings of the National Academy of Sciences.
[18] B. Hann,et al. TGFβ1 Inhibition Increases the Radiosensitivity of Breast Cancer Cells In Vitro and Promotes Tumor Control by Radiation In Vivo , 2011, Clinical Cancer Research.
[19] Susan M. Chang,et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[21] G. Tortora,et al. LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis , 2008, Molecular Cancer Therapeutics.
[22] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[23] Mark Payne,et al. Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.
[24] J. Nickel,et al. TGF-&bgr; family co-receptor function and signaling , 2018, Acta biochimica et biophysica Sinica.
[25] Li-Qing Zhao,et al. Tumor-derived transforming growth factor-β is critical for tumor progression and evasion from immune surveillance. , 2014, Asian Pacific journal of cancer prevention : APJCP.